Clinical validation of the influence of p-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors

Kostakoglu L., Elahi N., Kiratli P., Ruacan S., Sayek I., Baltali E., ...More

JOURNAL OF NUCLEAR MEDICINE, vol.38, no.7, pp.1003-1008, 1997 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 7
  • Publication Date: 1997
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1003-1008
  • Hacettepe University Affiliated: Yes


We prospectively studied 48 patients with either breast cancer (30 patients) or lung cancer (18 patients) to ascertain the relationship between the degree of accumulation of Tc-99m-sestamibi and the expression of p-glycoprotein in tumor tissues. Methods: During initial presentation (37 patients) or post-therapy evaluation (11 patients), the patients underwent contemporaneous Tc-99m-sestamibi imaging and biopsy (30 patients) or surgery (18 patients). The interval between surgery/biopsy and imaging Varied between 3 and 15 days. All patients had radiologically detectable tumors. Immunohistochemical studies were performed on paraffin sections using a monoclonal antibody, JSB-1, developed against the internal epitope of p-glycoprotein. Tumor-to-background ratios were correlated with the level of p-glycoprotein expression determined by immunohistochemical studies. Results: Our results showed an inverse correlation between the tumor-to-background ratios of Tc-99m-sestamibi and the density of p-glycoprotein expression in tumor tissues. The values for the tumor-lo-background ratios were significantly lower for those tumors expressing p-glycoprotein at high levels than those with scattered and no expression (p < 0.01 and p < 0.001, respectively). Conclusion: Although our results warrant further studies at the molecular revel using PCR techniques after the extraction of mRNA, our data strongly suggest that Tc-99m-sestamibi imaging is useful to noninvasively determine the presence of multidrug resistance in patients with malignant tumors.